Experiments using immortalized cell lines and patient-derived xenografts have illustrated that tumors harboring MET mutations and amplifications are responsive to MET blockade in the form of cell cycle arrest and/or apoptosis in vitro [54] and complete inhibition of tumor growth in vivo [55]. The gene discussed is MET; the disease is neoplasm.